Patents by Inventor Kevin Burke Miller
Kevin Burke Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9827216Abstract: The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.Type: GrantFiled: September 11, 2009Date of Patent: November 28, 2017Assignees: Nestec S.A., Institut CurieInventors: Eduardo Schiffrin, Kevin Burke Miller, Dominique Brassart, Olivier Jacques Lantz, Sebastian Diego Amigorena
-
Publication number: 20140342040Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides nutritional compositions having whey protein micelles and leucine. The nutritional compositions provide a sufficient amount of leucine to improve protein synthesis in humans, while also maintaining a low-viscosity fluid matrix and acceptable organoleptic properties.Type: ApplicationFiled: August 4, 2014Publication date: November 20, 2014Inventors: Kevin Burke Miller, Candis Diane Kvamme, Trent Stellingwerff, Lionel Jean Rene Bovetto
-
Patent number: 8871281Abstract: The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex.Type: GrantFiled: October 7, 2008Date of Patent: October 28, 2014Assignee: Nestec S.A.Inventor: Kevin Burke Miller
-
Patent number: 8853148Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides nutritional compositions having whey protein micelles and leucine. The nutritional compositions provide a sufficient amount of leucine to improve protein synthesis in humans, while also maintaining a low-viscosity fluid matrix and acceptable organoleptic properties.Type: GrantFiled: March 9, 2011Date of Patent: October 7, 2014Assignee: Nestec S.A.Inventors: Kevin Burke Miller, Candis Diane Kvamme, Trent Stellingwerff, Lionel Jean Rene Bovetto
-
Patent number: 8815312Abstract: Disclosed is a method and composition for nutritional compositions containing glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.Type: GrantFiled: May 24, 2007Date of Patent: August 26, 2014Assignee: Nestec S.A.Inventors: Anne Falk, Zamzam (Fariba) Roughead, Kevin Burke Miller, Satya Jonnalagadda, Norman Alan Greenberg, Kala Marie Kaspar, Julie Swanson
-
Publication number: 20130129838Abstract: Nutritional compositions having the potential to reduce metabolic acid load and methods of making and using the nutritional compositions are provided. In an embodiment, the present disclosure provides methods of selecting and administering nutritional compositions to patients. The methods may include modifications to calculating a metabolic acid potential of a nutritional composition, calculating a base content of a nutritional composition and subtracting the base content from the acid content to determine a potential renal acid load (“PRAL”) value. The present disclosure also provides computer implemented processes for predicting PRAL values.Type: ApplicationFiled: December 21, 2010Publication date: May 23, 2013Applicant: NESTEC S.A.Inventors: Kevin Burke Miller, Zamzam Kabiry Roughead, Jennifer Rae Mager, Douglas Richard Bolster, Norman Alan Greenberg
-
Publication number: 20130065822Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides nutritional compositions having whey protein micelles and leucine. The nutritional compositions provide a sufficient amount of leucine to improve protein synthesis in humans, while also maintaining a low-viscosity fluid matrix and acceptable organoleptic properties.Type: ApplicationFiled: March 9, 2011Publication date: March 14, 2013Applicant: NESTEC S.A.Inventors: Kevin Burke Miller, Candis Diane Kvamme, Trent Stellingwerff, Lionel Jean Rene Bovetto
-
Patent number: 8329646Abstract: The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof. The invention further provides nutritional products for such administration, including orally-administrable nutritional products.Type: GrantFiled: November 28, 2006Date of Patent: December 11, 2012Assignee: Nestec S.A.Inventors: Michael John Tisdale, Norman Alan Greenberg, Helen Laura Eley, Kevin Burke Miller
-
Publication number: 20120308525Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including a high protein component and one or more exogenous nucleotides. The nutritional compositions can be specifically used to accelerate and improve wound healing in a mammal.Type: ApplicationFiled: November 19, 2010Publication date: December 6, 2012Applicant: NESTEC S.A.Inventors: Norman Alan Greenberg, Kevin Burke Miller, Zamzam (Fariba) Kabiry Roughead
-
Publication number: 20120195873Abstract: Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition including whey protein, and Vitamin D. The nutritional composition and exercise can be specifically used to attenuate the loss of functional status, especially in the elderly.Type: ApplicationFiled: July 15, 2010Publication date: August 2, 2012Applicant: NESTEC S.A.Inventors: Kevin Burke Miller, Ingo Arne Jurk, Zamzam Kabiry Roughead
-
Publication number: 20110229521Abstract: The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently augment or enhance the immunocompetence of an immune cell and the immunogenecity of a tumor cell of a subject undergoing anti-cancer therapy-induced apoptosis and tumor-cell-enhanced immunogenicity such that the innate and adaptive immune functions and normal physiology of the immune cell are preserved, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell and immunogenecity of the tumor cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.Type: ApplicationFiled: September 11, 2009Publication date: September 22, 2011Inventors: Eduardo Schiffrin, Kevin Burke Miller, Dominique Brassart
-
Publication number: 20110229447Abstract: The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject undergoing anti-cancer therapy-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.Type: ApplicationFiled: September 11, 2009Publication date: September 22, 2011Inventors: Eduardo Schiffrin, Kevin Burke Miller, Dominique Brassart
-
Publication number: 20110223136Abstract: The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.Type: ApplicationFiled: September 11, 2009Publication date: September 15, 2011Inventors: Eduardo Schiffrin, Kevin Burke Miller, Dominique Brassart, Olivier Jacques Lantz, Sebastian Diego Amigorena
-
Publication number: 20110077198Abstract: The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent protein kinase. The compositions and methods of the present invention further include at least one potentiator that further enhances the inhibition of phosphorylation by PKR-I.Type: ApplicationFiled: October 3, 2008Publication date: March 31, 2011Inventors: Michael John Tisdale, Helen Laura Eley, Steve Thomas Russell, Kevin Burke Miller
-
Publication number: 20110028382Abstract: The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex.Type: ApplicationFiled: October 7, 2008Publication date: February 3, 2011Inventor: Kevin Burke Miller
-
Publication number: 20090148545Abstract: Disclosed is a method and composition for nutritional compositions containing -glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, -glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, -glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.Type: ApplicationFiled: May 24, 2007Publication date: June 11, 2009Inventors: Anne Falk, Zamzam Roughead, Kevin Burke Miller, Satya Jonnalagadda, Norman Alan Greenberg, Kala Marie Kaspar, Julie Swanson
-
Publication number: 20090105123Abstract: The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof.Type: ApplicationFiled: November 28, 2006Publication date: April 23, 2009Inventors: Michael John Tisdale, Norman Alan Greenberg, Helen Laura Eley, Kevin Burke Miller